@article{2945353b3bd8486696b0f7ec190da87e,
title = "A Fluid Challenge Test for the Diagnosis of Occult Heart Failure",
abstract = "A right heart catheterization with measurements of pulmonary artery wedge pressure (PAWP) may be necessary for the diagnosis of left heart failure as a cause of pulmonary hypertension or unexplained dyspnea. Diagnostic cutoff values are a PAWP of ≥ 15 mm Hg at rest or a PAWP of ≥ 25 mm Hg during exercise. However, accurate measurement of PAWP can be challenging and heart failure may be occult. Left heart catheterization, with measurement of left ventricular end-diastolic pressure, may also be indecisive. Measurements are then best repeated in stress conditions. Exercise is an option, but the equipment is not universally available, and interpretation can be difficult in patients with wide respiratory pressure swings. An alternative is offered by a fluid challenge. Studies have gathered data supporting infusion of 500 mL or 7 mL/kg saline and a PAWP of 18 mm Hg as a diagnostic cutoff. The procedure is simple and does not take much catheterization laboratory time. Combining echocardiography with invasive measurements may increase the diagnostic accuracy of diastolic dysfunction. Cardiac output after a fluid challenge may be of prognostic relevance.",
keywords = "dyspnea, exercise pulmonary hypertension, fluid challenge, heart failure, pulmonary artery wedge pressure, pulmonary hypertension",
author = "Michele D'Alto and David Badesch and Eduardo Bossone and Borlaug, {Barry A.} and Evan Brittain and Marc Humbert and Robert Naeije",
note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. D. has served on the advisory board/provided consulting for Actelion/Johnson & Johnson, Merck Sharp & Dohme, Glaxo Smith Kline, United Therapeutics, and Ferrer. D. B. has served on the advisory or steering committees, Data Safety Monitoring Boards (DSMBs), or consulted for Acceleron, Actelion/Johnson & Johnson, Arena/United Therapeutics, Complexa, Liquidia, Pfizer, United Therapeutics, and United States Pulmonary Hypertension Scientific Registry; and has received grant support from Acceleron , Actelion/Johnson & Johnson, Altavant, Arena/United Therapeutics, Complexa, Liquidia, Reata, United Therapeutics , and United States Pulmonary Hypertension Scientific Registry. B. A. B. has received research funding from NIH/NHLBI [Grants R01 HL128526, U01 HL125205]; AstraZeneca , Corvia, Medtronic , Mesoblast, GlaxoSmithKline , and TENAX; and has served on the advisory board/provided consulting for Merck, Novartis , Lilly, and Novo Nordisk. M. H. reports grants and personal fees from Actelion, grants and personal fees from Bayer, grants and personal fees from GSK, personal fees from Merck, personal fees from United Therapeutics, and grants and personal fees from Acceleron. R. N. has served on DSMBs, or consulted for Actlion/Johnson & Johnson, United Therapeutics, Lung Biotechnology Corp, and AOP Orphan Pharma. All the disclosures declared are outside the submitted work. None declared (E. Bossone, E. Brittain). Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. D. has served on the advisory board/provided consulting for Actelion/Johnson & Johnson, Merck Sharp & Dohme, Glaxo Smith Kline, United Therapeutics, and Ferrer. D. B. has served on the advisory or steering committees, Data Safety Monitoring Boards (DSMBs), or consulted for Acceleron, Actelion/Johnson & Johnson, Arena/United Therapeutics, Complexa, Liquidia, Pfizer, United Therapeutics, and United States Pulmonary Hypertension Scientific Registry; and has received grant support from Acceleron, Actelion/Johnson & Johnson, Altavant, Arena/United Therapeutics, Complexa, Liquidia, Reata, United Therapeutics, and United States Pulmonary Hypertension Scientific Registry. B. A. B. has received research funding from NIH/NHLBI [Grants R01 HL128526, U01 HL125205]; AstraZeneca, Corvia, Medtronic, Mesoblast, GlaxoSmithKline, and TENAX; and has served on the advisory board/provided consulting for Merck, Novartis, Lilly, and Novo Nordisk. M. H. reports grants and personal fees from Actelion, grants and personal fees from Bayer, grants and personal fees from GSK, personal fees from Merck, personal fees from United Therapeutics, and grants and personal fees from Acceleron. R. N. has served on DSMBs, or consulted for Actlion/Johnson & Johnson, United Therapeutics, Lung Biotechnology Corp, and AOP Orphan Pharma. All the disclosures declared are outside the submitted work. None declared (E. Bossone, E. Brittain). Publisher Copyright: {\textcopyright} 2020",
year = "2021",
month = feb,
doi = "10.1016/j.chest.2020.08.019",
language = "English (US)",
volume = "159",
pages = "791--797",
journal = "Diseases of the chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",
}